Proteomics and bioinformatics approaches for the identification of plasma biomarkers to detect Parkinson's disease

Dong,Wenwen; Qiu,Chang; Gong,Dawei; Jiang,Xu; Liu,Wan; Liu,Weiguo; Zhang,Li; Zhang,Wenbin

doi:10.3892/etm.2019.7888

Proteomics and bioinformatics approaches for the identification of plasma biomarkers to detect Parkinson's disease

Authors:
- Wenwen Dong
- Chang Qiu
- Dawei Gong
- Xu Jiang
- Wan Liu
- Weiguo Liu
- Li Zhang
- Wenbin Zhang
View Affiliations

Affiliations: Department of Functional Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Neurology, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: August 14, 2019 https://doi.org/10.3892/etm.2019.7888
Pages: 2833-2842
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to screen for biomarkers of Parkinson's disease (PD) using proteomics and bioinformatics approaches. PD patients were divided into three groups: Those without surgery (PD1 group); those who had undergone deep brain stimulation (DBS) surgery without electrode stimulation (PD2 group); and those who had undergone DBS surgery with 1 month of electrode stimulation (PD3 group). The non‑Parkinson control group (CK group) was also involved. Quantitative proteomic analysis of human sera was performed through the use of tandem mass tag markers and liquid chromatography‑mass spectrometry (LC‑MS)‑based techniques. For the proteins with quantitative information, a systematic bioinformatics analysis was then performed, including protein annotation, functional classification, functional enrichment and cluster analysis based on functional enrichment. Of the 739 proteins identified, quantitative information was available for 644. With regard to differential expression, 18 upregulated and 21 downregulated proteins were screened in the PD1/CK comparison group; 12 upregulated and 12 downregulated proteins in the PD2/PD1 comparison group; and 16 upregulated and 19 downregulated proteins in the PD3/PD2 comparison group. Coiled‑coil domain‑containing protein 154 (CCDC154) and tripartite motif‑containing protein 3 (TRIM3) were key proteins involved in the molecular mechanisms of PD, participating in intracellular vesicle, ubiquitin protein ligase and transition metal ion‑binding activities. After DBS surgery, desert hedgehog protein (DHH) was downregulated, whereas neuropilin‑2 (NRP2) was upregulated; these participated in the ensheathment of neurons and the semaphorin receptor complex, respectively. The expression level of chloride intracellular channel protein 1 (CLIC1) was increased after 1 month of electrode stimulation following DBS. By combining proteomic approaches and LC‑MS methods, significant proteins including CCDC154, TRIM3, DHH, NRP2 and CLIC1 were detected with high specificity and sensitivity. These may be used as novel biomarkers for early diagnosis of PD and the future development of treatments.

View Figures

View References

1	Ma XW and Guo RY: Dose-dependent effect of Curcuma longa for the treatment of Parkinson's disease. Exp Ther Med. 13:1799–1805. 2017. View Article : Google Scholar : PubMed/NCBI
2	Kuroda K, Tatara K, Takatorige T and Shinsho F: Effect of physical exercise on mortality in patients with Parkinson's disease. Acta Neurol Scand. 86:55–59. 1992. View Article : Google Scholar : PubMed/NCBI
3	Fan JY, Chang BL and Wu YR: Relationships among depression, anxiety, sleep, and quality of life in patients with Parkinson's disease in Taiwan. Parkinsons Dis. 2016:40401852016.PubMed/NCBI
4	Warner TT and Schapira AH: Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 53 (Suppl 3):S16–S25. 2003. View Article : Google Scholar : PubMed/NCBI
5	Cummings JL and Mendez MF: Alzheimer's disease: Cognitive and behavioral pharmacotherapy. Conn Med. 61:543–552. 1997.PubMed/NCBI
6	Spitzer AL and Hakim EW: Parkinson's disease: The interplay of medical and surgical treatment options with physical therapy. Acute Care Perspectives. 17:82008.
7	Olanow CW: The pathogenesis of cell death in Parkinson's disease-2007. Mov Disord. 22 (Suppl 17):S335–S342. 2007. View Article : Google Scholar : PubMed/NCBI
8	Blandini F and Armentero MT: Animal models of Parkinson's disease. FEBS J. 279:1156–1166. 2012. View Article : Google Scholar : PubMed/NCBI
9	Pienaar IS, Daniels WM and Götz J: Neuroproteomics as a promising tool in Parkinson's disease research. J Neural Transm (Vienna). 115:1413–1430. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M and Glucksman MJ: Neuroproteomics: Expression profiling of the brain's proteomes in health and disease. Neurochem Res. 29:1317–1331. 2004. View Article : Google Scholar : PubMed/NCBI
11	Monti C, Colugnat I, Lopiano L, Chiò A and Alberio T: Network analysis identifies disease-specific pathways for parkinson's disease. Mol Neurobiol. 55:370–381. 2018. View Article : Google Scholar : PubMed/NCBI
12	Kiesmann M, Chanson JB, Godet J, Vogel T, Schweiger L, Chayer S and Kaltenbach G: The movement disorders society criteria for the diagnosis of Parkinson's disease dementia: Their usefulness and limitations in elderly patients. J Neurol. 260:2569–2579. 2013. View Article : Google Scholar : PubMed/NCBI
13	Tyanova S, Temu T and Cox J: The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc. 11:2301–2319. 2016. View Article : Google Scholar : PubMed/NCBI
14	Okuda S, Yamada T, Hamajima M, Itoh M, Katayama T, Bork P, Goto S and Kanehisa M: KEGG Atlas mapping for global analysis of metabolic pathways. Nucl Acids Res 36 (Web Server Issue). W423–W426. 2008. View Article : Google Scholar
15	Horton P, Park KJ, Obayashi T and Nakai K: Protein subcellular localization prediction with WoLF PSORT. Asian Pacific Bioinformatics Conference. 39–48. 2006.
16	Meincke U and Kosinski CM: Treatment of mental disorders in patients with Parkinson's disease. Fortschr Neurol Psychiatr. 78:279–287. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
17	Peters M, Fitzpatrick R, Doll H, Playford D and Jenkinson C: Does self-reported well-being of patients with Parkinson's disease influence caregiver strain and quality of life? Parkinsonism Relat Disord. 17:348–352. 2011. View Article : Google Scholar : PubMed/NCBI
18	Schapira AH and Jenner P: Etiology and pathogenesis of Parkinson's disease. Mov Disord. 26:1049–1055. 2011. View Article : Google Scholar : PubMed/NCBI
19	Xu H, Wang Y, Song N, Wang J, Jiang H and Xie J: New progress on the role of glia in iron metabolism and iron-induced degeneration of dopamine neurons in Parkinson's disease. Front Mol Neurosci. 10:4552018. View Article : Google Scholar : PubMed/NCBI
20	Isacson O and Chung CY: Rab3b for the treatment and prevention of Parkinson's disease. US. 2011.
21	Liao W, Zhao R, Lu L, Zhang R, Zou J, Xu T, Wu C, Tang J, Deng Y and Lu X: Overexpression of a novel osteopetrosis-related gene CCDC154 suppresses cell proliferation by inducing G2/M arrest. Cell Cycle. 11:3270–3279. 2012. View Article : Google Scholar : PubMed/NCBI
22	Volles MJ and Lansbury PT Jr: Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 41:4595–4602. 2002. View Article : Google Scholar : PubMed/NCBI
23	Islam MS, Nolte H, Jacob W, Ziegler AB, Pütz S, Grosjean Y, Szczepanowska K, Trifunovic A, Braun T, Heumann H, et al: Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease. Hum Mol Genet. 25:5365–5382. 2016.PubMed/NCBI
24	Volz TJ, Farnsworth SJ, King JL, Riddle EL, Hanson GR and Fleckenstein AE: Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. J Pharmacol Exp Ther. 323:738–745. 2007. View Article : Google Scholar : PubMed/NCBI
25	Tanji K, Kamitani T, Mori F, Kakita A, Takahashi H and Wakabayashi K: TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies. Neurobiol Dis. 38:210–218. 2010. View Article : Google Scholar : PubMed/NCBI
26	Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, et al: Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA. 101:10810–10814. 2004. View Article : Google Scholar : PubMed/NCBI
27	Hoernke M, Koksch B and Brezesinski G: Influence of the hydrophobic interface and transition metal ions on the conformation of amyloidogenic model peptides. Biophys Chem. 150:64–72. 2010. View Article : Google Scholar : PubMed/NCBI
28	Medical Advisory Secretariat: Deep brain stimulation for Parkinson's disease and other movement disorders: An evidence-based analysis. Ont Health Technol Assess Ser. 5:1–56. 2005.
29	Escudero M, de la Cruz RR and Delgado-García JM: A physiological study of vestibular and prepositus hypoglossi neurones projecting to the abducens nucleus in the alert cat. J Physiol. 458:539–560. 1992. View Article : Google Scholar : PubMed/NCBI
30	Dong X, Chen K, Cuevas-Diaz DR, You Y, Sloan SA, Zhang Y, Zong S, Cao Q, Barres BA and Wu JQ: Comprehensive identification of long non-coding RNAs in purified cell types from the brain reveals functional LncRNA in OPC fate determination. PLoS Genetics. 11:e10056692015. View Article : Google Scholar : PubMed/NCBI
31	Cariboni A, Davidson K, Rakic S, Maggi R, Parnavelas JG and Ruhrberg C: Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: Implications for the aetiology of hypogonadotropic hypogonadism. Hum Mol Genet. 20:336–344. 2011. View Article : Google Scholar : PubMed/NCBI
32	Milton RH, Abeti R, Averaimo S, DeBiasi S, Vitellaro L, Jiang L, Curmi PM, Breit SN, Duchen MR and Mazzanti M: CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia. J Neurosci. 28:11488–11499. 2008. View Article : Google Scholar : PubMed/NCBI
33	Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, et al: Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 69:1445–1452. 2012. View Article : Google Scholar : PubMed/NCBI